SCHEMBL1856595

SCHEMBL1856595

COC(=O)C(CCCc1ccccc1)CCc1ccc(Oc2ccccc2C#N)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 4/20 0.52
LPAR1 Q92633 3/20 0.52
LPAR5 Q9H1C0 2/20 0.52
POLB P06746 1/20 0.47
GAA P10253 1/20 0.47
CYP3A4 P08684 1/20 0.44
FFAR1 O14842 1/20 0.41
ALDH1A1 P00352 3/20 0.40
EZH2 Q15910 1/20 0.40
LPAR3 Q9UBY5 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
ADRB2 P07550 1/20 0.39
CYP2D6 P10635 1/20 0.39
ADRB3 P13945 1/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
CASR P41180 1/20 0.39
SLC6A3 Q01959 1/20 0.39
KCNH2 Q12809 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1861512 0.89 LPAR1 (0.55) MAPK14LPAR1LPAR5POLBGAA
SCHEMBL1855203 0.86 CTSG (0.47) POLBALDH1A1RAB9AMMP2MMP3
SCHEMBL1856368 0.84 PLAAT3 (0.50) FFAR1ALDH1A1MMP2MMP3
SCHEMBL1855993 0.82 LTA4H (0.49) ALDH1A1NPC1RAB9AMMP2MMP3
SCHEMBL1855703 0.82 ALDH1A1 (0.54) LPAR1LPAR5GAAALDH1A1NPC1
SCHEMBL1859451 0.82 FFAR1 (0.44) LPAR1LPAR5FFAR1MMP2MMP3
SCHEMBL1858392 0.81 ALDH1A1 (0.57) GAAALDH1A1NPC1RAB9AMMP2
SCHEMBL1859940 0.80 GRIK1 (0.51) POLBCYP2D6MMP2MMP3SMN1; SMN2
SCHEMBL3466543 0.79 MMP12 (0.51) POLBMMP2MMP3
SCHEMBL1858600 0.78 GRIK1 (0.54) POLBNPC1RAB9ACYP2D6MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110105544-A1 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER CRYSTAX PHARMACEUTICALS, S.L. (ES) 2011-05-05 US disclosed
WO-2009080722-A2 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER CRYSTAX PHARMACEUTICALS, S.L. (ES) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105544-A1 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AKR1C3, TPD52L2, HCCS MAPK14 3286/4885LPAR1 1222/4885LPAR5 2011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.